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Experimental Details 
 
General considerations 
Unless otherwise specified, all air- and moisture-sensitive compounds were manipulated 
using glovebox or using standard Schlenk line techniques with an N2 atmosphere. Anhydrous 
tetrahydrofuran (THF) was purchased from Aldrich in 18 L Pure-PacTM containers. 
Anhydrous acetonitrile, benzene, dichloromethane, diethyl ether, and THF were purified by 
sparging with nitrogen for 15 minutes and then passing under nitrogen pressure through a 
column of activated A2 alumina (Zapp’s). Acetonitrile-d3 and chloroform-d1, were purchased 
from Cambridge Isotopes, dried over calcium hydride, and vacuum transferred prior to use. 
Benzene-d6 was also purchased from Cambridge Isotope Laboratories, Inc., dried over 
sodium/benzophenone ketyl and vacuum transferred prior to use. Unless indicated otherwise, 
all commercial chemicals were used as received. Pd(PPh3)4, Ni(OTf)2, and Pd(MeCN)4(BF4)2 
were purchased from Strem. 1,3,5-tribromobenzene, ZnCl2, potassium tert-butoxide, tBuLi, 
and nBuLi were purchased from Alfa Aesar. Chlorodiisopropylphosphine was purchased 
from Acros Organics. 2-bromotoluene and 1,3-dibromobenzene were purchased from Sigma-
Aldrich. 2-bromo-4-(tert-butyl)-toluene was synthesized according to literature procedure.1 
1H, 13C, and 31P NMR spectra were recorded on Varian Mercury 300 MHz or Varian 
INOVA-500 or 600 MHz spectrometers at room temperature. Chemical shifts for 1H and 13C 
NMR data are reported with respect to internal deuterated solvent.2 31P NMR chemical 
shifts are reported with respect to the deuterated solvent used to lock the instrument. 
Elemental analyses were performed by Complete Analysis Laboratories, Inc., Parsippany, NJ 
and Robertson Microlit Laboratories, Ledgewood, NJ.  
 
Scheme S1. Synthesis of 1a and 1b 
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Synthesis of A (R = tBu) 
To an oven-dried Schlenk tube fitted with a screw-in Teflon stopper was added 2-bromo-4-
(tert-butyl)-toluene (4.87 g, 21.5 mmol) and 73 mL THF under nitrogen. The solution was 
cooled to -78ºC and then tBuLi solution (1.7M in pentane, 26 mL, 44.2 mmol) was added via 
syringe or canula transferred under nitrogen atmosphere. The solution was stirred at -78ºC 
for one hour. ZnCl2 (2.05 g, 15.1 mmol) was then added as solid to the mixture under 
positive pressure of N2, then the mixture was allowed to warm to room temperature and 
stirred for 2 h. A solution of tribromobenzene (2.03 g, 6.45 mmol) in dry, degassed THF (30 
mL) was prepared in an inert atmosphere glovebox and canula transferred under N2 to the 
Zn-complex solution. Pd(PPh3)4 (1.24 g, 1.08 mmol) was then added as solid into the mixture 
under nitrogen. The reaction mixture was heated to 85ºC and stirred for 14 h. The product 
formation was checked by GC-MS. Cooled reaction mixture to room temperature, and then 
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water (20 mL) was added. Volatiles were removed via rotary evaporation. The mixture was 
extracted with CH2Cl2 (three times). The combined organic fraction was dried over MgSO4, 
filtered, and dried under vacuum. Recrystallization from CH2Cl2/MeOH afforded the clean 
product as white solid in 79% yield (2.63 g,  5.09 mmol). 1H NMR (300 MHz, CDCl3) δ 7.37 
(d, J= 2.1 Hz, 3H, aryl-H), 7.34 (s, 3H, aryl-H), 7.33 (s, 3H, aryl-H), 7.31 (d, J= 2.2 Hz, 3H, 
aryl-H), 2.36 (s, 9H, CH3), 1.33 (s, 27H, tert-butyl-H) ppm. 13C NMR (126 MHz, CDCl3) δ 
148.95 (s), 141.98 (s), 141.45 (s), 132.60 (s), 130.34 (s), 128.83 (s), 127.27 (s), 124.46 (s), 
34.61 (s), 31.61 (s), 20.34 (s) ppm. MS (m/z): calcd, 516.3756 (M+); 516.3739 (FAB-MS, 
M+). 
 
Synthesis of B (R = H) 
Similar protocol to the synthesis of A with the starting reagent 2-bromotoluene was used to 
make B in 77% yield. The NMR spectra of the product match those of literature.3  
 
Synthesis of 1b (R = H) 
The synthesis of 1b was adapted and modified from an analogous literature procedure.4 
Potassium tert-butoxide (5.10 g, 45.5 mmol) was added under N2 to an oven-dried Schlenk 
tube fitted with a screw-in Teflon stopper. THF (140 mL) was then added to the Schlenk tube 
under nitrogen. The solution was cooled to -78ºC. nBuLi solution (2.5 M in hexane, 14.4 mL, 
36.1 mmol) was added slowly via syringe under N2 over 15 min. The mixture was stirred at -
78ºC for 20 min. A solution of A (3.84 g, 11.0 mmol) in dry, degassed THF (20 mL) was 
canula transferred slowly to the cold superbase solution under nitrogen. The resulting 
solution turned blue then purple after all of A has been added. The mixture was stirred at -
78ºC for 40 min then allowed to warm to room temperature and stirred for 2 h. Upon stirring 
for 2 hr at r.t., the homogeneous solution became a heterogeneous suspension with wine-red 
color precipitate. The suspension was cooled to -78ºC then chlorodiisopropylphosphine (6.3 
mL, 39.6 mmol) was added via syringe to the reaction mixture under dinitrogen atmosphere. 
The reaction mixture turned clear yellow-brown color after all of the 
chlorodiisopropylphosphine was added. The mixture was allowed to warm to room 
temperature and stirred overnight. The solvent was removed in vacuo. Degassed Et2O and 
saturated citric acid solution were added to the residue. The aqueous fraction was discarded, 
and the organic layer was washed two more times with degassed water. The organic fraction 
was collected, dried over MgSO4, and filtered. Removal of solvent under vacuum gave light 
yellow solid residue. The residue was washed with CH3CN three times to give the clean 
product 1 as white solid in 76% yield (5.8 g, 8.3 mmol). 
1H NMR (500 MHz, C6D6) δ 7.67 (dd, 3H, aryl-H), 7.54 (s, 3H, central aryl-H), 7.44 (dd, 
3H, aryl-H), 7.13-7.21 (m, 6H, aryl-H), 2.91 (s, 6H, CH2), 1.61 (m, 6H, CH(CH3)2), 0.91 (dd, 
36H, CH(CH3)2) ppm. 31P NMR (121 MHz, C6D6) δ 11.37 ppm. 13C NMR (126 MHz, C6D6) 
δ 142.40 (d, J = 3.4 Hz), 142.14 (s), 138.04 (d, J = 8.1 Hz), 131.17 (d, J = 11.4 Hz), 130.79 
(s), 130.22 (s), 127.67 (s), 125.91 (d, J = 2.1 Hz), 27.65 (s), 27.47 (s), 23.82 (d, J = 16.8 Hz), 
19.74 (dd, J = 13.0, 6.6 Hz) ppm. MS (m/z): calcd, 696.4143 (M+); 697.4254 (FAB-MS, 
M+H). 
 
Synthesis of 1a (R = tBu) 
Similar protocol to synthesize 1b was carried out to make 1a in 70% yield. 
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1H NMR (300 MHz, C6D6) δ 7.69 (s, 3H, aryl-H), 7.67 (dd, 3H, aryl-H), 7.60 (d, 3H, aryl-
H), 7.32 (dd, 3H, aryl-H), 3.02 (s, 6H, CH2), 1.65 (m, 6H, CH(CH3)2), 1.28 (s, 27H, tert-
butyl-H), 0.99 (dd, 36H, CH(CH3)2) ppm. 31P NMR (121 MHz, C6D6) δ 10.78 ppm. 13C 
NMR (126 MHz, C6D6) δ 148.52 (d, J = 2.1 Hz), 142.70 (s), 142.22 (d, J = 3.3 Hz), 134.88 
(d, J = 8.0 Hz), 130.89 (d, J = 10.9 Hz), 130.33 (s), 124.77 (s), 34.54 (s), 31.61 (s), 27.32 (s), 
27.15 (s), 23.81 (d, J = 16.9 Hz), 19.86 (dd, J = 23.3, 13.1 Hz) ppm. MS (m/z): calcd, 
864.6021 (M+); 865.6099 (FAB-MS, M+H). 
 
Synthesis of 2b-Pd 
1b (100 mg, 0.144 mmol) was transferred into an oven-dried J. Young NMR tube. A solution 
of Pd(MeCN)4(BF4)2 (64 mg, 0.144 mmol) in CD3CN (1 mL) was added to the J. Young 
tube. The J. Young tube was sealed with the fitted Teflon cap, and the mixture was allowed 
to react for 2 h at room temperature where everything became homogeneous yellow solution.  
1H and 31P NMR spectra were taken immediately after 2 hr where the product was beginning 
to convert to 3b-Pd. 2b-Pd could not be isolated cleanly without further conversion to 3b-
Pd, thus, the NMR spectra collected contained peaks that correspond to the minor 3b-Pd 
species in the mixture. NMR peak assignments were done in comparison to 3b-Pd and the 
similar Pd-complex supported by diphosphine ligand variant 2c-Pd. 1H NMR (300 MHz, 
CD3CN) δ 7.81 (b, 1H, aryl-H), 7.75 (s, 1H, aryl-H), 7.67 (app d, J= 1.3 Hz, 2H, aryl-H), 
7.52 – 7.42 (m, 10H, aryl-H), 7.28 (m, 1H, aryl-H), 3.69 (b, 4H, unbound phosphine arm 
CH2), 2.91 (s, 2H, unbound phosphine arm CH2), 2.46 – 2.31 (m, 6H, CH), 1.98 (s, 6H, 
CH3CN), 1.30 (app dd, J= 15.9, 8.1 Hz, 24H, bound phosphine arm CH(CH3)2), 0.86 (app 
dd, J= 12.2, 7.1 Hz, 12H, unbound phosphine arm CH(CH3)2) ppm. 31P NMR (121 MHz, 
CD3CN) δ 39.99 (s, 2P), 13.57 (s, 1P) ppm. 13C NMR (126 MHz, CD3CN) δ 143.95 (s), 
142.78 (s), 142.21 (s), 141.10 (s), 132.96 (s), 132.65 (s), 131.68 (s), 131.35 (s), 131.04 (s), 
130.86 (s), 130.42 (s), 129.93 (s), 129.74 (s), 129.43 (s), 128.93 (s), 126.90 (s), 28.60 (s), 
28.07 – 27.00 (m), 23.86 (d, J = 15.6 Hz), 19.63 (d, J = 11.3 Hz), 19.31 (s), 18.88 (s) ppm. 
 
Scheme S2. Synthesis of 1c and 2c-Pd 
1 eq. Pd(MeCN)4(BF4)2
MeCN
[BF4]2
2c-Pd
(iPr)2
P
P(iPr)2PdMeCN
NCMePP
1c  
Synthesis of 1c 
Similar procedure to make 1b was carried out to synthesize 1c using 1,3-dibromobenzene as 
the starting reagent.5 The number of equivalents of reagents was adjusted to synthesize the 
diphosphine ligand variant. The product was isolated as pale yellow oil in 80% yield. 1H 
NMR (300 MHz, C6D6) δ 7.61 (app d, J= 7.7 Hz, 1H), 7.45 (app t, J= 1.6 Hz, 1H), 7.34 – 
7.21 (m, 5H), 7.17 – 7.01 (m, 5H), 2.85 (d, J = 1.7 Hz, 2H), 1.50 (dtd, J = 14.1, 7.0, 1.5 Hz, 
4H), 0.90 – 0.80 (dd, J = 12.4, 7.1 Hz, 24H) ppm. 31P NMR (121 MHz, C6D6) δ 11.64 (s) 
ppm. 13C NMR (126 MHz, C6D6) δ 142.47 (d, J = 3.4 Hz), 142.37 (s), 137.98 (d, J = 8.3 Hz), 
131.89 (s), 131.08 (d, J = 11.4 Hz), 130.71 (d, J = 2.6 Hz), 128.67 (d, J = 1.9 Hz), 127.96 (s), 
127.62 (s), 125.91 (d, J = 2.2 Hz), 27.41 (d, J = 22.1 Hz), 23.73 (d, J = 16.8 Hz), 19.67 (dd, J 
= 13.1, 9.4 Hz) ppm. MS (m/z): calcd, 490.2918 (M+); 490.2922 (FAB-MS, M+H). 
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Synthesis of 2c-Pd 
1c (1 g, 2.04 mmol) and Pd(MeCN)4(BF4)2 (906 mg, 2.04 mmol) were suspended in MeCN 
(80 mL). The reaction mixture was stirred at r.t. for 16 h or monitored by 31P NMR 
spectroscopy. Solvent was removed under vacuum, and the residue was washed with CH2Cl2 
to give the clean insoluble product as pale yellow solid in 65% yield (1.13g, 1.33 mmol). The 
product can be recrystallized from acetonitrile/toluene solution mixture. 1H NMR (300 MHz, 
CD3CN) δ 7.72 (s, 1H, aryl-H), 7.69 – 7.66 (m, 1H, aryl-H), 7.60 (app d, J= 1.5 Hz, 1H, aryl-
H), 7.58 (br s, 1H, aryl-H), 7.50 – 7.39 (m, 8H, aryl-H), 3.63 (s, 4H, CH2), 2.40 – 2.26 (m, 
4H, CH(CH3)2), 1.95 (s, theoretical 6H, CH3CN), 1.31 – 1.14 (m, 24H, CH(CH3)2) ppm. 31P 
NMR (121 MHz, CD3CN) δ 39.70 (s) ppm. 13C NMR (126 MHz, CD3CN) δ 143.12 (s), 
142.53 (s), 132.86 (t, J = 2.4 Hz), 132.41 (s), 130.86 (t, J = 2.9 Hz), 130.83 (s), 130.21 (s), 
129.64 (s), 129.36 (s), 129.30 (s), 28.17 (app t, J= 9.0 Hz), 26.75 (s), 19.07 (d, J= 22.3 Hz) 
ppm. Anal. Calcd. for: C36H50B2F8N2P2Pd (2c-Pd) (%): C, 50.70; H, 5.91; N, 3.28. Anal. 
Calcd. for: C38H53B2F8N3P2Pd (2c-Pd·MeCN) (%): C, 51.06; H, 5.98; N, 4.70. Found: C, 
51.06; H, 5.76; N, 4.72.  
 
Synthesis of 3a-Ni 
3a-Ni: M = Ni, R = tBu
3b-Ni: M = Ni, R = H
P
R
P
P
R
R
H
Ni
[OTf]2
 
A solution of 1a (500 mg, 0.72 mmol) in THF (10 mL) and a suspension of Ni(OTf)2 (513 
mg, 1.44 mmol) in CH3CN (20 mL) were added to an oven-dried Schlenk tube fitted with a 
screw-in Teflon stopper. The mixture was heated to 65ºC for 40 h where the color of the 
solution turned red-orange. The solvent was removed under vacuum. The dried residue was 
washed with Et2O to remove unreacted ligand. The rest of the residue was resuspended in 
minimal amount of CH3CN and filtered. Et2O was added carefully to the solution to 
precipitate out light purple solid. The light purple solid (possibly some nickel salts) was 
filtered off and discarded. The remaining filtrate was further concentrated in vacuo, and Et2O 
was added to the concentrated solution to precipitate/crystallize out the product cleanly as 
red-orange crystalline solid in 51% yield (450 mg, 0.37 mmol).  
1H NMR (300 MHz, CD3CN) δ 7.85 (d, J = 1.8 Hz, 1H, side aryl-H), 7.82 (d, J = 1.9 Hz, 1H, 
side aryl-H), 7.63 (d, J = 1.8 Hz, 1H, side aryl-H), 7.62 (d, J = 1.8 Hz, 1H, side aryl-H), 
7.48-7.54 (m, 3H, side aryl-H), 7.40 (s, 1H, side aryl-H), 7.24 (app d, J= 8.1 Hz, 1H, side 
aryl-H), 6.42 (app d, J= 3.4 Hz, 1H, central ring-H), 6.39 (s, 1H, central ring-H), 3.86 – 3.66 
(m, 2H, central ring sp3-H and CH2), 3.57 – 3.43 (m, 2H, CH2), 3.39 (d, J = 15.2 Hz, 1H, 
CH2), 3.21 (d, J = 15.3 Hz, 1H, CH2), 3.09 (dd, J = 15.4, 3.6 Hz, 1H, CH2), 2.85 – 2.69 (m, 
1H, CH), 2.58 – 2.43 (m, 2H, CH), 2.30 – 2.18 (m, 1H, CH), 2.17 – 2.03 (m, 1H, CH), 2.04 – 
1.94 (m, 1H, CH), 1.69 (dd, J = 15.3, 8.1 Hz, 3H, CH3 ), 1.50 (dd, J = 15.8, 7.1 Hz, 3H, 
CH3), 1.45 – 1.27 (m, 12H, CH3), 1.44 (s, 9H, tert-butyl-CH3), 1.42 (s, 9H, tert-butyl-CH3), 
1.32 (s, 9H, tert-butyl-CH3), 1.16 (app dd, J= 17.6, 7.1 Hz, 3H, CH3), 0.92 (app dd, J= 12.4, 
6.8 Hz, 3H, CH3), 0.66 (app ddd, J= 14.7, 11.7, 7.0 Hz, 6H, CH3), 0.51 – 0.35 (m, 6H, CH3) 
ppm. 31P NMR (121 MHz, CD3CN) δ 73.99 (dd, J = 14.0, 5.1 Hz), 63.76 (dd, J = 45.3, 5.1 
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Hz), 31.44 (dd, J = 45.2, 14.0 Hz) ppm. 13C NMR (126 MHz, CD3CN) δ 152.77 (s), 152.20 
(s), 151.93 (s), 136.18 (s), 134.47 (s), 134.21 (s), 133.48 (s), 132.01 (s), 131.67 (s), 131.36 
(s), 131.26 (s), 131.21 – 131.05 (m), 128.62 (s), 128.43 (d, J = 18.0 Hz), 127.99 (s), 126.56 
(s), 125.49 (s), 123.98 (s), 123.71 (s), 120.35 (s), 101.24 (s), 93.20 (s), 82.99 (s), 67.62 (s), 
38.01 (d, J = 16.9 Hz), 34.97 (s), 34.81 (s), 30.87 (s), 30.76 (s), 30.60 (s), 28.61 (d, J = 22.0 
Hz), 28.16 (d, J = 21.3 Hz), 27.14 (d, J = 18.5 Hz), 26.79 (d, J = 21.5 Hz), 25.61 (s), 23.25 
(s), 23.11 (s), 22.87 (s), 20.98 (s), 20.83 (s), 20.48 (s), 20.13 (s), 20.02 (s), 19.40 (s), 18.00 
(s), 17.80 (s), 17.47 (s), 17.12 (s), 16.55 (s), 15.75 (s), 14.70 (s) ppm. Anal. Calcd. for: 
C59H87F6NiO6P3S2 (%): C, 57.99; H, 7.18. Found: C, 57.84; H, 7.03. λmax (CH3CN, nm), ε 
(M-1cm-1): 502, 1.61 x 103; 427, 2.89 x 103; 359, 7.84 x 103; 291, 1.28 x 103.  
 
Synthesis of 3b-Ni 
3b-Ni was synthesized in 60% yield using an analogous protocol to make 3a-Ni. 
1H NMR (300 MHz, CD3CN) δ 7.96 (m, 1H, aryl-H), 7.88 (m, 1H, aryl-H), 7.53-7.58 (m, 
8H, aryl-H), 7.42 (app d, J= 6.3 Hz, 1H, aryl-H), 7.38 (app d, J= 4.6 Hz, 1H, aryl-H), 7.30 
(app d, J= 7.4 Hz, 1H), 6.43 (app d, J= 3.2 Hz, 1H, central aryl-H), 6.24 (s, 1H, central aryl-
H), 3.87 (ddd, J = 25.4, 14.4, 8.5 Hz, 2H, central ring sp3-H, CH2), 3.50 (ddd, J = 20.7, 14.8, 
10.0 Hz, 3H, CH2), 3.27 (d, J = 14.8 Hz, 1H, CH2), 3.17 (dd, J = 15.4, 4.2 Hz, 1H, CH2), 
2.73 (m, 1H, CH), 2.50 (m, 2H, CH), 2.39 (m, 1H, CH), 2.11 (m, 1H, CH), 1.99 (m, 1H, 
CH), 1.72 (dd, J = 17.2, 7.2 Hz, 3H, CH3), 1.52 – 1.27 (m, 15H, CH3), 1.17 (dd, J = 17.7, 7.1 
Hz, 3H, CH3), 0.89 (dd, J = 12.2, 5.5 Hz, 3H, CH3), 0.71 – 0.58 (m, 6H, CH3), 0.51 (dd, J = 
18.3, 7.0 Hz, 3H, CH3), 0.35 (dd, J = 17.0, 7.4 Hz, 3H, CH3) ppm. 31P NMR (121 MHz, 
CD3CN) δ 75.69 (dd, J = 14.0, 4.7 Hz), 63.92 (dd, J = 43.7, 4.8 Hz), 31.74 (dd, J = 43.6, 14.0 
Hz) ppm. 13C NMR (126 MHz, CD3CN) δ 137.86 (s), 137.08 (s), 135.42 (s), 134.75 (d, J = 
4.3 Hz), 134.54 (d, J = 5.9 Hz), 131.88 (d, J = 7.9 Hz), 131.75 (s), 131.62 (d, J = 5.7 Hz), 
131.38 (s), 131.11 (s), 131.01 (s), 130.14 (s), 129.90 (s), 129.24 (s), 129.11 (s), 127.48 (s), 
127.17 (d, J = 6.8 Hz), 126.36 (d, J = 11.6 Hz), 123.03 (s), 121.42 (s), 120.48 (s), 101.87 (s), 
92.93 (d, J = 9.3 Hz), 82.75 (s), 38.16 (d, J = 22.9 Hz), 29.03 (d, J = 22.1 Hz), 28.47 (d, J = 
21.4 Hz), 27.33 (d, J = 18.4 Hz), 27.00 (d, J = 21.6 Hz), 23.99 (d, J = 18.5 Hz), 22.67 (s), 
21.36 (d, J = 5.6 Hz), 20.98 (d, J = 4.1 Hz), 20.81 (d, J = 21.8 Hz), 20.41 (d, J = 38.3 Hz), 
20.36 (s), 19.51 (s), 18.28 (s), 18.08 (d, J = 3.4 Hz), 17.99 (d, J = 5.0 Hz), 17.84 (s), 17.74 
(d, J = 4.4 Hz), 16.90 (d, J = 6.5 Hz), 16.29 (d, J = 4.3 Hz), 15.08 (d, J = 3.1 Hz) ppm. 
 
Synthesis of 3a-Pd 
 
3a-Pd: M = Pd, R = tBu
3b-Pd: M = Pd, R = H
P
R
P
P
R
R
H
Pd
[BF4]2
 
 
A solution of Pd(MeCN)4(BF4)2 (25.7 mg, 0.0578 mmol) in CH3CN (5 mL) was added to 1a 
(50 mg, 0.0578 mmol). The resulting suspension was stirred and heated to 55°C for 4 h 
where the mixture became homogeneous yellow. The solvent was removed in vacuo to give 
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the product as a yellow solid analytically clean by 31P NMR spectroscopy. Attempts to grow 
X-ray quality single crystals have been unsuccessful to date. This material was utilized in the 
subsequent step without further purification.  
1H NMR (300 MHz, CD3CN) δ 7.80 (s, 1H, aryl-H), 7.77 (d, J = 1.6 Hz, 1H, aryl-H), 7.61 – 
7.55 (m, 4H, aryl-H), 7.49 (d, J = 8.1 Hz, 1H, aryl-H), 7.25 (d, J = 8.2 Hz, 1H aryl-H), 7.22 
(d, J = 1.7 Hz, 1H, aryl-H), 6.54 (app d, J= 3.5 Hz, 1H, central ring-H), 6.50 (app d, J= 1.3 
Hz, 1H, central ring-H), 4.19 (m, 1H, central ring sp3-H), 3.62-3.75 (m, 2H, CH2), 3.46-3.57 
(m, 2H, CH2), 3.29 (d, J = 14.6 Hz, 1H, CH2), 3.05 (dd, J = 14.8, 3.2 Hz, 1H, CH2), 2.89 (m, 
1H, CH), 2.51 (m, 2H, CH), 2.30 (m, 1H, CH), 2.16 (m, 1H, CH), 2.04 (m, 1H, CH), 1.69 
(dd, J = 17.0, 7.2 Hz, 3H, CH3), 1.41 (s, 9H, tert-butyl CH3), 1.40 (s, 9H, tert-butyl CH3), 
1.53 – 1.08 (m, 18H, CH3), 1.27 (s, 9H, tert-butyl CH3), 0.69 (ddd, J = 24.6, 15.7, 7.0 Hz, 
6H, CH3), 0.45 (ddd, J = 21.2, 17.1, 7.1 Hz, 9H, CH3) ppm. 31P NMR (121 MHz, CD3CN) δ 
87.34 (dd, J = 37.8, 32.6 Hz), 80.09 (dd, J = 65.6, 32.4 Hz), 40.29 (dd, J = 65.6, 38.0 Hz) 
ppm. 13C NMR (126 MHz, CD3CN) δ 153.48 (s), 152.83 (s), 152.58 (s), 136.06 (s), 135.88 
(s), 135.18 (d, J = 4.2 Hz), 133.77 (d, J = 20.9 Hz), 132.99 (d, J = 5.1 Hz), 132.15 (d, J = 5.2 
Hz), 131.57 (s), 131.47 (s), 129.30 (s), 128.93 (s), 128.84 (s), 128.65 (s), 127.28 (d, J = 5.6 
Hz), 126.31 (s), 124.39 (s), 124.33 (s), 124.15 (s), 107.54 (s), 102.09 (d, J = 20.4 Hz), 94.12 
(dd, J = 24.1, 4.7 Hz), 38.60 (d, J = 15.2 Hz), 35.55 (s), 35.38 (d, J = 1.9 Hz), 31.43 (s), 
31.32 (s), 31.23 (s), 27.80 (d, J = 12.8 Hz), 27.67 (d, J = 6.0 Hz), 27.54 (d, J = 13.9 Hz), 
27.36 (d, J = 16.7 Hz), 26.89 (d, J = 15.5 Hz), 24.12 (d, J = 31.7 Hz), 22.93 (d, J = 16.8 Hz), 
21.51 (d, J = 37.5 Hz), 20.06 (s), 20.02 (s), 19.95 (d, J = 5.2 Hz), 19.68 (d, J = 3.4 Hz), 18.47 
(s), 18.24 (s), 18.21 (s), 18.10 (s), 17.88 (s), 17.87 (s), 17.21 (d, J = 4.0 Hz), 16.36 (d, J = 4.1 
Hz), 15.34 (d, J = 3.0 Hz) ppm. 
 
Synthesis of 3b-Pd 
3b-Pd was synthesized analogously to 3a-Pd. 
1H NMR (300 MHz, CD3CN) δ 7.95 (m, 1H, aryl-H), 7.86 (dd, J = 6.8, 2.1 Hz, 1H, aryl-H), 
7.68 – 7.61 (m, 2H, aryl-H), 7.58 – 7.52 (m, 3H, aryl-H), 7.48 – 7.43 (m, 3H, aryl-H), 7.36 
(m, 2H, aryl-H), 7.31 (app d, J= 7.5 Hz, 1H, aryl-H), 6.55 (app d, J= 3.4 Hz, 1H, central 
ring-H), 6.36 (app m, 1H, central ring-H), 4.30 (m, 1H, central ring sp3-H), 3.84 – 3.49 (m, 
4H, CH2), 3.32 (d, J = 15.1 Hz, 1H, CH2), 3.13 (dd, J = 14.7, 3.5 Hz, 1H, CH2), 2.84 (m, 1H, 
CH), 2.50 (m, 2H, CH), 2.35 (m, 1H, CH), 2.17 (m, 1H, CH), 2.02 (m, 1H, CH), 1.69 (dd, J 
= 17.3, 7.3 Hz, 3H, CH3), 1.45 – 1.41 (m, 3H, CH3), 1.39 – 1.37 (m, 3H, CH3), 1.35 – 1.32 
(m, 3H, CH3), 1.31 – 1.24 (m, 6H, CH3), 1.21 – 1.10 (m, 6H, CH3), 0.85 (dd, J = 12.2, 7.1 
Hz, 3H, CH3), 0.67 (dd, J = 13.7, 7.1 Hz, 3H, CH3), 0.61 – 0.55 (m, 3H, CH3), 0.53 – 0.46 
(m, 3H, CH3), 0.39 (dd, J = 17.4, 7.3 Hz, 3H, CH3) ppm. 31P NMR (121 MHz, CD3CN) δ 
86.08 (dd, J = 37.0, 32.4 Hz), 78.94 (dd, J = 63.3, 32.9 Hz), 38.16 (dd, J = 63.4, 37.6 Hz) 
ppm. 13C NMR (126 MHz, CD3CN) δ 138.82 (s), 136.97 (s), 136.68 (t, J = 5.1 Hz), 135.28 
(d, J = 4.5 Hz), 134.46 (t, J = 3.8 Hz), 132.99 (d, J = 5.5 Hz), 132.41 (d, J = 5.4 Hz), 131.78 
(t, J = 6.2 Hz), 131.48 (s), 131.45 (s), 130.51 (d, J = 8.3 Hz), 130.49 (s), 129.82 (d, J = 4.6 
Hz), 129.73 (d, J = 2.1 Hz), 129.51 (s), 129.05 (dd, J = 10.1, 6.7 Hz), 127.58 (s), 127.58 (s), 
127.25 (d, J = 7.0 Hz), 127.25 (d, J = 7.0 Hz), 125.20 (s), 107.83 (s), 101.32 (d, J = 19.3 Hz), 
93.64 (dd, J = 24.6, 5.1 Hz), 38.44 (d, J = 21.7 Hz), 27.87 (s), 27.71 (s), 27.66 (s), 27.52 (d, J 
= 6.7 Hz), 27.42 (s), 27.29 (s), 23.66 (d, J = 31.5 Hz), 23.42 (d, J = 16.6 Hz), 21.11 (d, J = 
37.8 Hz), 20.03 (d, J = 3.2 Hz), 19.93 (d, J = 4.8 Hz), 18.82 (d, J = 33.8 Hz), 18.51 (s), 18.44 
– 18.32 (m), 18.24 (d, J = 2.2 Hz), 17.98 (d, J = 1.9 Hz), 17.87 (d, J = 2.2 Hz), 17.31 (d, J = 
 S9 
4.1 Hz), 16.65 (d, J = 4.1 Hz), 15.51 (d, J = 3.1 Hz) pm. λmax (CH3CN, nm), ε (M-1cm-1): 
381, 8.66 x 103; 331, 1.06 x 104; 288, 1.35 x 104. 
 
Synthesis of 4a-Ni 
4a-Ni: M = Ni, R = tBu
4b-Ni: M = Ni, R = H
[OTf]
P
P
P
R
R R
Ni
 
 
To a solution of 3a-Ni (50 mg, 0.041 mmol) in CH3CN (5 mL) was added sodium acetate 
(3.4 mg, 0.041 mmol). The mixture was stirred at room temperature for 16 h monitored by 
31P NMR spectroscopy. The resulting red-orange solution was filtered and dried under 
vacuum. The dried residue was taken up in minimal amount of THF to make a concentrated 
solution, and then hexanes were added to precipitate out product. The precipitate was taken 
up in diethyl ether. The ether soluble material was dried under vacuum to give the clean 
product in 65% yield (29 mg, 0.027 mmol). Attempts to obtain crystalline material have been 
unsuccessful thus far.  
1H NMR (300 MHz, CD3CN) δ 7.68 (d, J = 2.0 Hz, 1H, aryl-H), 7.49 (dt, J = 4.9, 2.4 Hz, 
2H, aryl-H), 7.37 (s, 1H, aryl-H), 7.34 (s, 1H, aryl-H), 7.28 (app d, J= 0.9 Hz, 2H, aryl-H), 
7.23 (app d, J= 8.0 Hz, 1H, aryl-H), 7.15 (s, 1H, aryl-H), 6.47 (app m, 1H, central aryl-H), 
4.56 (s, 1H, central aryl-H), 3.46 – 3.28 (m, 3H, CH2), 3.15 (ddd, J = 17.2, 12.4, 2.9 Hz, 2H, 
CH2), 2.76 (t, J = 12.4 Hz, 1H, CH2), 2.39 (m, 1H, CH), 2.21 (m, 2H, CH), 1.86 (m, 3H. 
CH), 1.40 (s, 9H, tert-butyl CH3), 1.37 – 1.32 (m, 3H, CH3), 1.32 (s, 9H, tert-butyl CH3), 
1.29 (s, 9H, tert-butyl CH3), 1.25 (m, 3H, CH3), 1.20 – 1.14 (m, 3H, CH3), 1.09 (m, 6H, 
CH3), 1.01 – 0.88 (m, 6H, CH3), 0.82-0.72 (m, 9H, CH3), 0.60 – 0.47 (m, 6H, CH3). 
31P NMR (121 MHz, CD3CN) δ 55.39 (dd, J = 69.3, 7.6 Hz), 35.52 (d, J = 69.3 Hz), 24.51 
(d, J = 7.5 Hz) ppm. 13C NMR (126 MHz, CD3CN) δ 156.65 (s), 152.88 (s), 151.25 (s), 
150.88 (s), 142.95 (s), 141.97 (d, J = 10.6 Hz), 138.01 (d, J = 6.8 Hz), 135.08 (s), 134.38 (s), 
131.71 (s), 131.28 (d, J = 4.2 Hz), 130.94 (s), 130.35 (d, J = 8.0 Hz), 127.06 (s), 125.67 (s), 
125.40 (s), 125.02 (s), 123.99 (s), 123.87 (s), 122.20 (d, J = 8.2 Hz), 117.56 (s), 88.39 (d, J = 
94.4 Hz), 70.30 (d, J = 13.1 Hz), 68.70 (s), 35.37 (s), 35.15 (s), 34.86 (s), 31.52 (s), 31.46 (s), 
31.37 (s), 27.05 (d, J = 17.1 Hz), 26.65 (d, J = 15.7 Hz), 26.17 (s), 26.02 (d, J = 7.4 Hz), 
25.97 (d, J = 5.3 Hz), 25.43 (d, J = 16.1 Hz), 23.36 (s), 23.25 (d, J = 10.6 Hz), 23.00 (s), 
20.25 (d, J = 4.6 Hz), 20.19 (d, J = 3.2 Hz), 19.99 (s), 19.92 (d, J = 6.5 Hz), 19.59 (s), 19.31 
(s), 18.84 (s), 17.92 (s), 17.88 (s), 16.92 (s), 16.57 (d, J = 2.8 Hz), 16.10 (s) ppm. Anal. 
Calcd. for: C58H86F3NiO3P3S2 (%): C, 64.98; H, 8.09. Found: C, 64.87; H, 7.99. λmax 
(CH3CN, nm), ε (M-1cm-1): 477, 3.72 x 103; 384, 1.13 x 104; 325, 6.78 x 103 
 
Synthesis of 4b-Ni 
4b-Ni was synthesized analogously to 4a-Ni in 67% yield. The crystalline product can be 
obtained through vapor diffusion of hexanes into a THF solution of the material.  
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1H NMR (500 MHz, CD3CN) δ 7.66 (m, 1H, aryl-H), 7.51 (app d, J= 7.7 Hz, 1H, aryl-H), 
7.46 – 7.40 (m, 3H, aryl-H), 7.35 (app d, J= 6.9 Hz, 1H, aryl-H), 7.33 – 7.25 (m, 3H, aryl-H), 
7.22 – 7.13 (m, 2H, aryl-H), 7.10 (m, 1H, aryl-H), 6.51 (m, 1H, central aryl-H), 4.56 (app td, 
J= 4.8, 2.0 Hz, 1H, central aryl-H), 3.36 (m, 3H, CH2), 3.23 – 3.12 (m, 2H, CH2), 2.78 (app t, 
J= 12.3 Hz, 1H, CH2), 2.40 (ddd, J = 14.2, 11.1, 7.1 Hz, 1H, CH), 2.16 (ddt, J = 19.6, 14.0, 
6.9 Hz, 2H, CH), 1.85 (ddd, J = 15.3, 14.7, 7.1 Hz, 2H, CH), 1.27 (ddd, J = 23.1, 13.8, 6.7 
Hz, 6H, CH3), 1.17 (dd, J = 17.6, 10.5 Hz, 3H, CH3), 1.12 – 1.00 (m, 9H, CH3), 0.93 (dd, J = 
17.2, 6.9 Hz, 3H, CH3), 0.81 – 0.69 (m, 9H, CH3), 0.62 (dd, J = 14.9, 7.3 Hz, 3H, CH3), 0.53 
(dd, J = 14.3, 6.9 Hz, 3H, CH3) ppm. 31P NMR (121 MHz, CD3CN) δ 57.24 (dd, J = 68.6, 
7.5 Hz), 34.53 (d, J = 68.6 Hz), 24.91 (d, J = 7.2 Hz) ppm. 13C NMR (126 MHz, CD3CN) δ 
155.73 (s), 142.76 (s), 142.29 (d, J = 11.9 Hz), 138.11 (s), 137.98 (d, J = 7.0 Hz), 137.03 (d, 
J = 4.1 Hz), 131.68 (d, J = 3.5 Hz), 131.40 (d, J = 4.8 Hz), 130.44 (s), 130.38 (s), 129.96 (s), 
129.36 – 129.25 (m), 129.32 – 129.14 (m), 128.58 (s), 127.87 (s), 127.83 (s), 127.60 (s), 
127.28 (s), 126.69 (s), 126.59 (s), 124.79 (d, J = 7.4 Hz), 88.51 (d, J = 87.3 Hz), 68.97 (d, J = 
13.4 Hz), 66.74 (s), 26.90 (d, J = 17.2 Hz), 26.57 (d, J = 16.1 Hz), 26.33 (dd, J = 13.2, 5.1 
Hz), 25.82 (d, J = 16.1 Hz), 25.14 (s), 25.01 (s), 24.69 (s), 23.53 (d, J = 6.1 Hz), 22.83 (s), 
22.47 (s), 19.96 (d, J = 6.0 Hz), 19.74 (d, J = 7.4 Hz), 19.40 (d, J = 6.4 Hz), 19.17 (dd, J = 
11.3, 4.5 Hz), 18.01 (s), 17.89 (s), 17.75 (d, J = 3.1 Hz), 17.64 (s), 16.62 (s), 16.39 (d, J = 2.9 
Hz), 15.87 (s). 
 
Synthesis of 4a-Pd 
4a-Pd: M = Pd, R = tBu
4b-Pd: M = Pd, R = H
P
P
P
R
R R
Pd
[BF4]
 
 
To a solution of 3a-Pd (66 mg, 0.058 mmol) in CH3CN (6 mL) was added sodium acetate (5 
mg, 0.058 mmol). The mixture turned bright orange yellow over 6 h and was stirred at room 
temperature for 16 h or monitored by 31P NMR spectroscopy. The solvent was removed 
under vacuum to give yellow-orange residue. The residue was taken up in benzene and 
hexanes were added to precipitate out the clean product as waxy, oily material. The waxy 
residue was dried under vacuum to yield the clean product as yellow-orange solid in 61% 
yield (37 mg, 0.035 mmol). Several recrystallization conditions have been attempted, but no 
crystalline material has been obtained thus far.  
1H NMR (300 MHz, CD3CN) δ 7.77 (d, J = 2.0 Hz, 1H, aryl-H), 7.48 (dd, J = 8.1, 2.0 Hz, 
1H, aryl-H), 7.43 (s, 1H, aryl-H), 7.36 – 7.30 (m, 1H, aryl-H), 7.24 (s, 1H, aryl-H), 7.22 (s, 
1H, aryl-H), 7.10 (d, J = 1.9 Hz, 1H, aryl-H), 7.03 (d, J = 1.9 Hz, 1H, central aryl-H), 5.47 
(d, J = 1.9 Hz, 1H, central aryl-H), 3.46 – 3.17 (m, 1H, CH2), 3.08 (app dd, J= 12.9, 3.4 Hz, 
1H, CH2), 2.78 (m, 1H, CH2), 2.47 (m, 1H, CH), 2.16 (m, 1H, CH), 1.97 (m, 1H, CH), 1.84 
(m, 1H, CH), 1.58 (m, 1H, CH), 1.36 (s, 9H, tertbutyl- CH3), 1.33 – 1.29 (m, 3H, CH3), 1.27 
(s, 9H, tertbutyl- CH3), 1.23 (s, 9H, tertbutyl- CH3), 1.14 (m, 9H, CH3), 1.05 (m, 3H, CH3), 
1.03 – 0.92 (m, 9H, CH3), 0.78 – 0.68 (m, 3H, CH3), 0.66 – 0.62 (m, 3H, CH3), 0.59 – 0.48 
(m, 6H, CH3) ppm. 31P NMR (121 MHz, CD3CN) δ 62.55 (dd, J = 80.0, 7.9 Hz), 32.14 (d, J 
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= 80.1 Hz), 27.05 (d, J = 7.7 Hz) ppm. 13C NMR (126 MHz, CD3CN) δ 153.30 (s), 151.60 – 
151.41 (m), 151.30 (d, J = 1.9 Hz), 150.99 (d, J = 2.5 Hz), 142.34 (s), 141.48 (d, J = 11.0 
Hz), 137.65 (d, J = 5.2 Hz), 136.37 – 135.94 (m), 133.67 (d, J = 3.2 Hz), 130.70 (d, J = 8.2 
Hz), 129.27 (s), 127.36 (s), 126.09 (s), 125.57 (s), 124.65 (s), 124.47 (s), 122.52 (d, J = 8.9 
Hz), 120.82 (s), 92.77 (s), 92.01 (d, J = 12.3 Hz), 79.71 (s), 35.53 (s), 35.30 (s), 35.03 (s), 
31.62 (s), 31.54 (s), 31.52 (s), 27.68 (s), 26.76 (d, J = 7.8 Hz), 26.67 (d, J = 6.0 Hz), 26.34 
(d, J = 9.8 Hz), 25.14 (d, J = 9.9 Hz), 24.31 (s), 23.47 (s), 23.12 (s), 20.40 (d, J = 5.2 Hz), 
20.34 (s), 20.27 (d, J = 8.0 Hz), 19.88 (d, J = 7.4 Hz), 19.56 (s), 19.27 (d, J = 4.9 Hz), 19.10 
(d, J = 3.4 Hz), 19.02 (d, J = 4.7 Hz), 18.83 (d, J = 2.8 Hz), 18.62 (s), 18.04 (d, J = 2.3 Hz), 
17.05 (d, J = 3.0 Hz), 16.51 (d, J = 1.9 Hz) ppm. 
 
Synthesis of 4b-Pd 
4a-Pd was synthesized analogously to 4b-Pd. Recrystallization via vapor diffusion of diethyl 
ether into a CH3CN solution of the material afforded the clean product as orange X-ray 
quality single crystals in 72% yield. 1H NMR (500 MHz, CD3CN) δ 7.74 (m, 1H, aryl-H), 
7.50 (m, 1H, aryl-H), 7.47 (m, 1H, aryl-H), 7.44 (m, 1H, aryl-H), 7.35 (m, 1H, aryl-H), 7.32 
(app d, J= 7.9 Hz, 1H, aryl-H), 7.29 (m, 1H, aryl-H), 7.22 – 7.18 (m, 2H, aryl-H), 7.08 (m, 
1H, aryl-H), 7.06 (m, 1H, central aryl-H), 5.52 (m, 1H, central aryl-H), 3.45 (m, 2H, CH2), 
3.38 – 3.27 (m, 2H, CH2), 3.14 (app dd, J= 12.9, 3.8 Hz, 1H, CH2), 2.83 (m, 1H, CH2), 2.48 
(m, 1H, CH), 2.18 (m, 1H, CH), 1.94 – 1.84 (m, 2H, CH), 1.79 (m, 1H, CH), 1.62 (m, 1H, 
CH), 1.25 (dd, J = 11.9, 6.9 Hz, 3H, CH3), 1.17 (dd, J = 11.7, 5.8 Hz, 3H, CH3), 1.14 – 1.07 
(m, 3H, CH3), 1.06 – 0.98 (m, 12H, CH3), 0.79 (dd, J = 16.6, 8.3 Hz, 3H, CH3), 0.72 (dd, J = 
13.4, 6.7 Hz, 3H, CH3), 0.67 (dd, J = 16.8, 7.4 Hz, 3H, CH3), 0.61 (dd, J = 7.0, 3.3 Hz, 3H, 
CH3), 0.58 (dd, J = 7.0, 1.9 Hz, 3H, CH3) ppm. 31P NMR (121 MHz, CD3CN) δ 64.67 (dd, J 
= 77.1, 8.0 Hz), 31.76 (d, J = 77.2 Hz), 27.41 (d, J = 8.1 Hz) ppm. 13C NMR (126 MHz, 
CD3CN) δ 150.87 (s), 142.40 (s), 141.95 (d, J = 10.8 Hz), 139.63 – 139.18 (m), 137.92 (d, J 
= 7.5 Hz), 136.81 (d, J = 3.5 Hz), 132.70 (d, J = 4.5 Hz), 132.62 (d, J = 3.5 Hz), 131.22 (s), 
130.96 (d, J = 8.3 Hz), 130.50 (s), 130.44 (s), 129.90 (s), 128.83 (s), 128.42 (s), 128.25 (d, J 
= 1.8 Hz), 127.91 (s), 127.66 (d, J = 2.1 Hz), 127.47 (s), 125.42 (d, J = 8.3 Hz), 121.23 (s), 
92.30 (d, J = 90.8 Hz), 90.38 (d, J = 16.6 Hz), 78.02 (s), 28.22 (s), 26.83 (d, J = 10.5 Hz), 
26.73 (d, J = 12.0 Hz), 26.43 (d, J = 10.2 Hz), 25.21 (s), 25.17 (s), 25.13 (s), 23.21 (s), 22.86 
(s), 20.59 (d, J = 8.8 Hz), 20.17 (d, J = 10.5 Hz), 19.98 (d, J = 2.5 Hz), 19.91 (s), 19.34 (d, J 
= 5.2 Hz), 19.20 (d, J = 3.4 Hz), 19.03 (d, J = 4.2 Hz), 18.71 (d, J = 3.0 Hz), 18.06 (s), 18.03 
(s), 17.11 (d, J = 3.1 Hz), 16.49 (d, J = 2.1 Hz) ppm. Anal. Calcd. for: C45H62BF4P3Pd (%): 
C, 60.79; H, 7.03. Found: C, 60.59; H, 6.87. λmax (CH3CN, nm), ε (M-1cm-1): 418, 4.53 x 103; 
350, 1.26 x 104 
 
 
 
 
 
 
 
 
 
 
 
 S12 
Nuclear Magnetic Resonance Spectra 
 
  
Figure S1. 1H (left, 300 MHz, CDCl3) and 31P (right, 121 MHz, CDCl3) NMR spectra of A 
 
 
Figure S2. 13C NMR (126 MHz, CDCl3) spectrum of A 
 
 
Figure S3. 1H (left, 300 MHz, C6D6) and 31P (right, 121 MHz, C6D6) NMR spectra of 1a 
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Figure S4. 13C NMR (126 MHz, C6D6) spectrum of 1a 
 
 
Figure S5. 1H (left, 300 MHz, C6D6) and 31P (right, 121 MHz, C6D6) NMR spectra of 1b 
 
 
Figure S6. 13C NMR (126 MHz, C6D6) spectrum of 1b 
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Figure S7. 1H (left, 300 MHz, C6D6) and 31P (right, 121 MHz, C6D6) NMR spectra of 1c 
 
 
Figure S8. 13C NMR (126 MHz, C6D6) spectrum of 1c 
 
 
Figure S9. 1H (left; 300 MHz, CD3CN) and 31P (right; 121 MHz, CD3CN) NMR spectra of 
2b-Pd. Note: the smaller impurity peaks correspond to the concurrent formation of 3b-Pd.  
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Figure S10. 13C NMR (126 MHz, CD3CN) spectrum of 2b-Pd. Note: the smaller impurity 
peaks correspond to the increasing formation of 3b-Pd during the reaction. 
 
 
Figure S11. 1H (left; 300 MHz, CD3CN) and 31P (right; 121 MHz, CD3CN)) NMR spectra of 
2c-Pd  
 
 
Figure S12. 13C NMR (126 MHz, CD3CN) spectrum of 2c-Pd 
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Figure S13. 1H NMR (300 MHz, CD3CN) spectrum of 3a-Ni 
 
 
Figure S14. 31P NMR (121 MHz, CD3CN) spectrum of 3a-Ni 
 
 
Figure S15. 13C NMR (126 MHz, CD3CN) spectrum of 3a-Ni 
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Figure S16. 1H-1H gCOSY(600 MHz, CD3CN) spectrum of 3a-Ni. The labeled peaks are the 
central-ring proton correlations 
 
Figure S17. 1H-13C gHSQC (600 MHz, CD3CN) spectrum of 3a-Ni 
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Figure S18. 1H-13C gHMBC (600 MHz, CD3CN) spectrum of 3a-Ni 
 
 
Figure S19. 1H NMR (300 MHz, CD3CN) spectrum of 3b-Ni 
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Figure S20. 31P NMR (121 MHz, CD3CN) spectrum of 3b-Ni 
 
 
Figure S21. 13C NMR (126 MHz, CD3CN) spectrum of 3b-Ni 
 
 
Figure S22. 1H NMR (300 MHz, CD3CN) spectrum of 3a-Pd 
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Figure S23. 31P NMR (121 MHz, CD3CN) spectrum of 3a-Pd 
 
 
Figure S24. 13C NMR (126 MHz, CD3CN) spectrum of 3a-Pd  
 
 
Figure S25. 1H NMR (300 MHz, CD3CN) spectrum of 3b-Pd 
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Figure S26. 31P NMR (121 MHz, CD3CN) spectrum of 3b-Pd 
 
 
Figure S27. 13C NMR (126 MHz, CD3CN) of 3b-Pd 
 
 
Figure S28. 1H NMR (300 MHz, CD3CN) spectrum of 4a-Ni 
 
 S22 
 
Figure S29. 31P NMR (121 MHz, CD3CN) spectrum of 4a-Ni 
 
 
Figure S30. 13C NMR (126 MHz, CD3CN) spectrum of 4a-Ni 
 
 
Figure S31. 1H NMR (300 MHz, CD3CN) spectrum of 4b-Ni 
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Figure S32. 31P NMR (121 MHz, CD3CN) spectrum of 4b-Ni 
 
 
Figure S33. 13C NMR (126 MHz, CD3CN) spectrum of 4b-Ni 
 
 
Figure S34. 1H NMR (300 MHz, CD3CN) spectrum of 4a-Pd 
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Figure S35. 31P NMR (121 MHz, CD3CN) spectrum of 4a-Pd 
 
 
Figure S36. 13C NMR (126 MHz, CD3CN) spectrum of 4a-Pd 
 
 
Figure S37. 1H NMR (500 MHz, CD3CN) spectrum of 4b-Pd 
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Figure S38. 31P NMR (121 MHz, CD3CN) spectrum of 4b-Pd 
 
 
Figure S39. 13C NMR (126 MHz, CD3CN) spectrum of 4b-Pd 
 
 S26 
 
Figure S40. 1H-1H gCOSY(600 MHz, CD3CN) spectrum of 4b-Pd. The labeled peaks are 
the central-aryl ring proton correlations 
 
 
Figure S41. 1H-13C gHSQC (600 MHz, CD3CN) spectrum of 4b-Pd 
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Figure S42. 1H-13C gHMBC (600 MHz, CD3CN) spectrum of 4b-Pd 
 
Crystallographic Information 
CCDC 920550 - 920553 contain the supplementary crystallographic data for this paper. 
These data can be obtained free of charge from The Cambridge Crystallographic Data Centre 
via www.ccdc.cam.ac.uk/data_request/cif. 
 
Refinement details  
In each case, crystals were mounted on a glass fiber or nylon loop using Paratone oil, then 
placed on the diffractometer under a nitrogen stream. Low temperature (100 K) X-ray data 
were obtained on a Bruker APEXII CCD based diffractometer (Mo sealed X-ray tube, Kα = 
0.71073 Å). All diffractometer manipulations, including data collection, integration and 
scaling were carried out using the Bruker APEXII software.6 Absorption corrections were 
applied using SADABS.7 Space groups were determined on the basis of systematic absences 
and intensity statistics and the structures were solved by direct methods using XS7 
(incorporated into SHELXTL) and refined by full-matrix least squares on F2. All non-
hydrogen atoms were refined using anisotropic displacement parameters. Hydrogen atoms 
were placed in idealized positions and refined using a riding model. The structure was 
refined (weighted least squares refinement on F2) to convergence. 
 
It should be noted that due to the size of these compounds, most crystals included solvent 
accessible voids, which tended to contain disordered solvent. In addition, due to a tendency 
to desolvate, the long range order of these crystals and amount of high angle data we were 
able to record was in some cases not ideal. These disordered solvent molecules were largely 
responsible for the alerts generated by the checkCIF protocol. For 3a-Ni, the disordered non-
coordinated solvents were removed using the SQUEEZE protocol included in PLATON8 
 S28 
(vide infra). We are confident this additional electron density is from the solvent molecules 
in the crystal lattice and not from unaccounted counter ions. 
 
Table S1. Crystal and refinement data for reported complexes. 
 3a-Ni 4b-Ni 4b-Pd 2c-Pd 
empirical 
formula 
C128 H188 F12 Ni2 O13 
P6 S4 
C100 H139 F6 Ni2 O8 P6 
S2 
C51 H68 B F4 P3 Pd 
C38 H53 B2 F8 N3 P2 
Pd 
formula 
wt 2594.26 1950.47 967.17 893.79 
T (K) 100 100 100 100 
a, Å 15.2622(7) 30.909(6) 9.7632(6) 13.0651(7) 
b, Å 20.3413(9) 9.6130(14) 13.8627(9) 19.8103(8) 
c, Å 23.5270(10) 33.956(6) 18.8685(11) 15.9572(8) 
α, deg 90 90 111.116(3) 90 
β, deg 103.125(2) 105.396(6) 96.691(3) 98.120(2) 
γ, deg 90 90 92.975(3) 90 
V, Å3 7113.2(5) 9727(3) 2353.9(3) 4088.7(3) 
Z 2 4 2 4 
cryst syst Monoclinic Monoclinic Triclinic Monoclinic 
space 
group P2(1) P2(1)/n P-1 P2(1)/c 
dcalcd, 
g/cm3 1.211 1.332 1.365 1.452 
θ range, 
deg 1.70-37.44 1.81-25.27 1.58-28.5 1.57-43.63 
µ, mm-1 0.460 0.595 0.546 0.600 
abs cor Semi-empirical from 
equivalents 
Semi-empirical from 
equivalents 
Semi-empirical from 
equivalents 
Semi-empirical from 
equivalents 
GOFc 0.985 1.311 1.070 1.372 
R1,a wR2b 
(I > 2σ(I)) 0.0618, 0.1647 0.0769, 0.1799 0.0538, 0.1035 0.0437, 0.1033 
 
a R1 = Σ||Fo|-|Fc|| / Σ|Fo|     b wR2 = { Σ [w(Fo2-Fc2)2] / Σ [w(Fo2)2] }1/2     c GOF = S = { Σ 
[w(Fo2-Fc2)2] / (n-p) }1/2 
 
Special refinement details for 3a-Ni 
The structure also contains four outer-sphere trifluoromethanesulfoante counter anions that 
were satisfactorily modeled. Two disordered tert-butyl methyl groups were modeled and split 
into two positions. Restraints were employed to treat the displacement parameters of one of 
the triflate molecules to an acceptable size. Benzene and tetrahydrofuran (THF) were used as 
the crystallization solvents. Accordingly, the compound crystallized with benzene and THF 
solvent molecules in the lattice. Four additional disordered THF solvent molecules, however, 
could not be satisfactorily modeled (see Figure S44 for depiction of solvent accessible 
voids). The SQUEEZE protocol contained with the program PLATON8 was used to generate 
a bulk solvent correction to the observed intensities. The results are appended to the CIF.  
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Figure S43. Solid-state structure of an enantiomer of 3a-Ni as 50% thermal ellipsoids. 
Hydrogen atoms, counter ions, and solvents are omitted for clarity. 
 
 
Figure S44. Unit cell packing of 3a-Ni displaying solvent accessible voids in yellow 
 
Special refinement details for 4b-Ni 
4b-Ni was crystallized from THF/hexanes mixture. Accordingly, the compound crystallized 
with two THF solvent molecules in the lattice.  The structure also contains two outer-sphere 
trifluoromethanesulfonate counterions that were satisfactorily modeled. Restraints were 
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employed to treat the displacement parameters of the methyl of an isopropyl group to an 
acceptable size. The relatively low level of completeness is due to poor crystal quality. This 
dataset represents the best of repeated collection attempts using crystals obtained under 
various crystallization conditions. 
 
 
Figure S45. Solid-state structure of an enantiomer of 4b-Ni as 50% thermal ellipsoids. 
Hydrogen atoms, counter ions, and solvents are omitted for clarity. 
 
 
Special refinement details for 4b-Pd 
Benzene was used as the solvent to crystallize the complex 4b-Pd. Accordingly, the 
compound crystallized with one benzene solvent molecule in the lattice. The structure 
contains an outer-sphere tetrafluoroborate counter anion that was slightly disordered and 
modeled with occupancy in two positions. 
 
 
Figure S46. Solid-state structure of 4b-Pd as 50% thermal ellipsoids. Hydrogen atoms, 
counter ions, and solvents are omitted for clarity. 
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Special refinement details for 2c-Pd 
The compound was crystallized from acetonitrile/toluene mixture. Accordingly, the 
compound crystallized with one acetonitrile in the lattice. The structure also contains two 
outer-sphere tetrafluoroborate counterion that were satisfactorily modeled. 
 
 
Figure S47. Solid-state structure of 2c-Pd as 50% thermal ellipsoids. Hydrogen atoms, 
counter ions, and solvents are omitted for clarity. 
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